RPG Life Sciences Ltd

RPG Life Sciences Ltd

RPG Life Sciences Ltd has received a certificate from MUFG Intime India Private Limited confirming compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, regarding dematerialisation of securities.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has published a newspaper advertisement regarding a special window for lodgment of transfer and dematerialization requests for physical securities sold or purchased prior to April 1, 2019.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Clarus Capital I and others.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has received an intimation from its subsidiary RPG Active Pharma Ltd regarding the approval of a Scheme of Amalgamation of Actis Generics Private Ltd with RPG Active Pharma Ltd under the Companies Act, 2013. The Scheme is subject to necessary approvals and is expected to result in benefits such as streamlined corporate structure, cost savings, and improved management oversight.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced the closure of its trading window for insiders from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has completed the acquisition of Actis Generics Private Limited, as per the share purchase agreement dated July 29, 2026. Actis has become a subsidiary of the company, effective September 24, 2026.

RPG Life Sciences Ltd

RPG Life Sciences Ltd clarified that there is no unpublished event or information that may have a bearing on the price or volume of its shares, attributing the recent increase in trading volume to market conditions.

RPG Life Sciences Ltd

The BSE has sought clarification from RPG Life Sciences Ltd regarding a significant movement in volume on September 24, 2026, indicating potential trading activity or market interest.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has informed that the Business Transfer Agreement (BTA) execution by its wholly owned subsidiary, RPG Active Pharma Limited, with Raghava Life Sciences Private Limited has been completed. The transfer of API Business will be effective from September 16, 2026.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has informed that its wholly owned subsidiary RPG Active Pharma Limited has allotted securities to investors ILSF and VJF for a total consideration of INR 243.33 crores, constituting 40% of the equity share capital of RPGAP.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has provided an update on its analyst/institutional call held on September 3, 2026, and made the relevant details available on its website.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced the dial-in details for an investor meet on September 3, 2026, where the company's management will provide an API business update.

RPG Life Sciences Ltd

RPG Life Sciences Ltd announces investors presentation, detailing subsidiary of API business into RPGAP for strategic focus, partnership with pharma-centric PE firm InvAscent, and acquisition of Actis Generics and Raghava Life Sciences for enhancing product portfolio and capacity.

RPG Life Sciences Ltd

RPG Life Sciences Ltd will host an investors/analyst call on September 3, 2026, to discuss the company's strategic announcement made on September 2, 2026.

RPG Life Sciences Ltd

RPG Life Sciences Ltd's wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), has acquired the Active Pharmaceutical Ingredients (API) and Intermediates business undertaking of Raghava Life Sciences Private Limited for up to ₹135 crore. The acquisition is expected to strengthen RPGAP's integrated API play and capture a larger share of the growing API market.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced the execution of a Business Transfer Agreement by its wholly owned subsidiary, RPG Active Pharma Limited, with Raghava Life Sciences Private Limited for the acquisition of Active Pharmaceutical Ingredients (APIs) and intermediates Businesses. The transaction involves the acquisition of a business with revenues of about Rs. 19 Crores in FY26, along with manufacturing facilities, R&D facility, and a portfolio of 29 API molecules.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has announced the execution of a Business Transfer Agreement by its wholly owned subsidiary, RPG Active Pharma Limited, to acquire the Active Pharmaceutical Ingredients (APIs) and intermediates businesses of Raghava Life Sciences Private Limited through a slump sale.

RPG Life Sciences Ltd

RPG Life Sciences Ltd cancelled its scheduled investor meet on September 2, 2026, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has informed about an Analyst/Institutional Investors Meet to be held on September 2, 2026, in Mumbai. The meeting will be participated by the company and will be held in a physical format. The details of the meeting are as follows: Date: September 2, 2026, Time: 10:00 A.M. IST, Venue: Mumbai, Mode: Physical, Nature of Meeting: Group Meet.

RPG Life Sciences Ltd

RPG Life Sciences Ltd has informed about the Schedule of Analyst/Institutional Investors Meet, to be participated by the Company on August 25, 2026, at 10:00 A.M. in Mumbai.